(Q35697595)

9 August 2017

1 reference

title

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes (English)

1 reference

9 August 2017

6

Dani Bolognesi

1 reference

9 August 2017

Tom Matthews

1

1 reference

9 August 2017

Miklos Salgo

2

1 reference

9 August 2017

Michael Greenberg

3

1 reference

9 August 2017

Jain Chung

4

1 reference

9 August 2017

Ralph DeMasi

5

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Nature Reviews Drug Discovery

9 August 2017

published in

1 reference

9 August 2017

volume

3

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

215-225

1 reference

Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.

9 August 2017

cites work

1 reference

Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome.

31 March 2020

1 reference

Antiretroviral-drug resistance among patients recently infected with HIV.

31 March 2020

1 reference

Antiretroviral therapy for previously treated patients

31 March 2020

1 reference

31 March 2020

1 reference

Mechanisms of viral membrane fusion and its inhibition

31 March 2020

1 reference

HIV fusion and its inhibition

31 March 2020

1 reference

Oligomeric structure of a prototype retrovirus glycoprotein

31 March 2020

1 reference

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

31 March 2020

1 reference

Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41

31 March 2020

1 reference

Structural rearrangements in the transmembrane glycoprotein after receptor binding

31 March 2020

1 reference

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

31 March 2020

1 reference

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex

31 March 2020

1 reference

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

31 March 2020

1 reference

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

31 March 2020

1 reference

Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage

31 March 2020

1 reference

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

31 March 2020

1 reference

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

31 March 2020

1 reference

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

31 March 2020

1 reference

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients

31 March 2020

1 reference

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

31 March 2020

1 reference

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

31 March 2020

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

31 March 2020

1 reference

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

31 March 2020

1 reference

Core structure of gp41 from the HIV envelope glycoprotein

31 March 2020

1 reference

Atomic structure of the ectodomain from HIV-1 gp41

31 March 2020

1 reference

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

31 March 2020

1 reference

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide

31 March 2020

1 reference

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

31 March 2020

1 reference

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

31 March 2020

1 reference

Novel therapies based on mechanisms of HIV-1 cell entry.

31 March 2020

1 reference

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

31 March 2020

1 reference

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

31 March 2020

1 reference

Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication

31 March 2020

1 reference

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

31 March 2020

1 reference

Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types

31 March 2020

1 reference

Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.

31 March 2020

1 reference

Strategies in the design of antiviral drugs

31 March 2020

1 reference

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1331

1 reference

9 August 2017

1 reference